Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts

Neuro-Oncology

Volumn 9, Issue 4, 2007, Pages 393-403

  Krauze, Michal T ^a   Noble, Charles O ^b,c   Kawaguchi, Tomohiro ^a   Drummond, Daryl ^c   Kirpotin, Dmitri B ^c   Yamashita, Yoji ^a   Kullberg, Erika ^b   Forsayeth, John ^a   Park, John W ^b   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Hermes Biosciences Inc   (United States)

Author keywords

Brain tumor; CED; CPT 11; Doxil; Irinotecan; Liposome; Xenograft

Indexed keywords

DOXORUBICIN; IRINOTECAN; LIPOSOME; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CONVECTION ENHANCED DELIVERY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; HUMAN CELL; INTRACRANIAL TUMOR; LIPOSOMAL DELIVERY; MALE; NONHUMAN; RAT; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; DRUG POTENTIATION; DRUG SCREENING; HALF LIFE TIME; SPRAGUE DAWLEY RAT; THERMODYNAMICS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CONVECTION; DOXORUBICIN; DRUG SYNERGISM; HALF-LIFE; HUMANS; LIPOSOMES; MALE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38449115418     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2007-019     Document Type: Article

References (36)

1. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-Oncology. 2000;2:45-59.
2. Huynh GH, Deen DF, Szoka FC Jr. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release. 2006;110:236-259.
3. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H. Intratumoral chemotherapy. Neurosurgery. 1995;37:1128-1145.
4. Giese A, Kucinski T, Knopp U, et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol. 2004;66:351-360.
5. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91:2076-2080.
6. Saito R, Bringas JR, Panner A, et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res. 2004;64:6858-6862.
7. Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat. 2006; 5:239-250.
8. Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enh an ced delivery in intracran ial tumors: pharmacology and efficacy. Cancer Res. 2006;66:2801-2806.
9. Yamashita Y, Saito R, Krauze MT, Noble CO, Kawaguchi T, Bankiewicz KS. Convection-enhanced delivery of liposomal doxorubicin in intra-cranial brain tumor xenografts. Targeted Oncol. 2006;1:79-85.
10. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir 2003;88(suppl):105-111.
11. Carpentier A, Laigle-Donadey F, Zohar S, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-Oncology. 2006;8:60-66.
12. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol. 2005;73: 57-69.
13. Mardor Y, Roth Y, Lidar Z, et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 2001; 61:4971-4973.
14. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691-743.
15. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818-1822.
16. Saito R, Bringas JR, McKnight TR, et al. Distribution of liposomes in to brain an d rat brain tu mor models by convection-en hanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004;64:2572-2579.
17. Krauze MT, McKnight TR, Yamashita Y, et al. Real-time visualization an d characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc. 2005;16:20-26.
18. Krauze MT, Saito R, Noble C, et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neuro-surg. 2005;103:923-929.
19. Saito R, Krauze MT, Bringas JR, et al. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol. 2005;196:381-389.
20. Drummond DC, Marx C, Guo Z, et al. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res. 2005;11:3392-3401.
21. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66:3271-3277.
22. Saito R, Krauze MT, Noble CO, et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-Oncology. 2006;8:205-214.
23. Ando M, Eguchi K, Shinkai T, et al. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomer-ase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. Br J Cancer. 1997;76:1494-1499.
24. Herben VM, ten Bokkel Huinink WW, Dubbelman AC, et al. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br J Cancer. 1997;76:1500-1508.
25. Hammond LA, Eckardt JR, Ganapathi R, et al. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin Cancer Res. 1998;4:1459-1467.
26. Bartlett GR. Colorimetric assay methods for free and phosphorylated glyceric acids. J Biol Chem. 1959;234:469-471.
27. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using prodrug approach. Exp Neurol. 2000;164:2-14.
28. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res. 1981;35:269-335.
29. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59:459-466.
30. Allen TM, Hansen CB, Lopes de Menezes DE. Pharmacokinetics of long-circulating liposomes. Adv Drug Del Rev. 1995;16:267-284.
31. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemo-sensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol. 1999;125:481-486.
32. Walker DH, Adami GR, Dold KM, Babiss LE. Misregulated expression of the cyclin dependent kinase 2 protein in human fibroblasts is accompanied by the inability to maintain a G2 arrest following DNA damage. Cell Growth Differ. 1995;6:1053-1061.
33. Karlseder J, Wissing D, Holzer G, et al. HSP70 overexpression mediates the escape of a doxorubicin-induced G2 cell cycle arrest. Biochem Biophys Res Commun. 1996;220:153-159.
34. Camphausen K, Purow B, Sproull M, et al. Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc Natl Acad Sci U S A. 2005;102:8287-8292.
35. Yamashita Y, Krauze MT, Kawaguchi T, et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-Oncology. 2007;9:20-28.
36. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intra-cerebral clysis in a rat glioma model. Neurosurgery. 2000;47:1391-1399.